Author: Mok, Hoyin; Cheng, Xing; Xu, Qi; Zengel, James R; Parhy, Bandita; Zhao, Jackie; Wang, C. Kathy; Jin, Hong
Title: Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350 Document date: 2012_2_16
ID: 3qdjmb2j_42
Snippet: Based on our study, MV vector is probably not suitable for delivery of the EBV gp350 antigen. Immunogenicity of adjuvanted gp350 protein vaccine has been demonstrated in young adults [29] , adjvanted gp350 might be the right approach for EBV vaccine development. The amount of gp350 delivered by MV is likely not sufficient to induce gp350 specific immune response. The F protein of RSV delivered by MV is more immunogenic than EBV gp350, however, ad.....
Document: Based on our study, MV vector is probably not suitable for delivery of the EBV gp350 antigen. Immunogenicity of adjuvanted gp350 protein vaccine has been demonstrated in young adults [29] , adjvanted gp350 might be the right approach for EBV vaccine development. The amount of gp350 delivered by MV is likely not sufficient to induce gp350 specific immune response. The F protein of RSV delivered by MV is more immunogenic than EBV gp350, however, additional evaluation of immunogenicity of MV-RSV F must be conduced before proceeding to testing this vaccine in humans.
Search related documents:
Co phrase search for related documents- additional evaluation and protein vaccine: 1
- additional evaluation and vaccine development: 1
- EBV vaccine development and vaccine development: 1
- human vaccine test and vaccine development: 1
- human vaccine test and vaccine test: 1, 2, 3
- immune response and MV vector: 1, 2, 3
- immune response and protein vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- immune response and right approach: 1
- immune response and specific immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- immune response and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- immune response and vaccine test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- immune response and young adult: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- MV vector and vaccine development: 1, 2
- protein vaccine and specific immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- protein vaccine and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- protein vaccine and vaccine test: 1, 2, 3
- specific immune response and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- specific immune response and young adult: 1, 2
- vaccine development and young adult: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date